[68Ga]Ga-PentixaFor, FLUDEOXYGLUCOSE (18F) clinical trials

A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a positron emission tomography (PET) imaging agent, versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma (MZL) exemplary for CXCR4-positive malignant lymphomas: a prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial (LYMFOR).

This study compares two types of body scans for people with marginal zone lymphoma (a type of cancer). It aims to see if a newer scan ([68Ga]Ga-PentixaFor PET/CT) is better or as good as the standard scan ([18F]FDG PET/CT) at finding cancer cells in the body.